Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
PT-141 (Bremelanotide)
Melanocortin agonist researched for sexual desire and arousal.
Plain-Language Label Highlights
Brand names: Vyleesi (bremelanotide)
Low sexual desire (HSDD) in premenopausal women, used on demand.
A shot you take before intimacy that works in the brain — not on blood flow — to help bring back sexual desire.
- •Nausea (very common, especially first dose)
- •Flushing
- •Headache
- •Injection-site reaction
- •Vomiting
- •Short-term spikes in blood pressure
- •Darkening of skin or gums with repeated use
- •Slowed heart rate
- •You have uncontrolled high blood pressure
- •You have known heart disease
- •You are pregnant or could become pregnant during use
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Mechanism of Action
A synthetic analog of α-MSH that activates melanocortin receptors (primarily MC4R) in the central nervous system. Unlike PDE5 inhibitors, it acts on neural pathways governing sexual desire rather than vascular flow.
Research Areas
Common Research Protocols
Single subcutaneous dose approximately 45 minutes before anticipated activity in approved indication.
Protocols summarized for educational reference from published research. Not dosing guidance.
Cited Research
Bremelanotide for hypoactive sexual desire disorder
Phase 3 RECONNECT trials supporting FDA approval.
Important Considerations
- •FDA-approved (Vyleesi) only for HSDD in premenopausal women.
- •Can cause nausea, flushing, transient blood pressure increases.
- •Avoid in uncontrolled hypertension or cardiovascular disease.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.